Second-generation antipsychotics did not improve outcomes and increased costs for patients with Alzheimer disease and psychosis.
Seitz
Dallas P
DP
Queen's University, Kingston, Ontario, Canada.
Gruneir
Andrea
A
Rochon
Paula A
PA